Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 19, 2025 06:30 ET | Source: Altimmune, Inc

Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial

Improvements observed in key non-invasive markers of fibrosis across treatment arms versus placebo, with continued reductions from 24-week timepoint Additional weight loss from 24 to 48 weeks with...
May 27, 2024 10:31 ET | Source: The Rosen Law Firm PA

GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALT

NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and...
May 09, 2024 14:52 ET | Source: The Rosen Law Firm PA

ALT INVESTOR NOTICE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALT

NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of...
February 19, 2024 16:53 ET | Source: The Rosen Law Firm PA

NATIONALLY RANKED ROSEN LAW FIRM Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT

NEW YORK, Feb. 19, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune,...